| Q47872845 | "Understanding the Role of Hypoxia inducible factor during neurodegeneration for new therapeutics opportunities". |
| Q37024261 | 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. |
| Q64269328 | A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS |
| Q26775401 | A comprehensive review of amyotrophic lateral sclerosis |
| Q64097917 | A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis |
| Q37305916 | A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. |
| Q36022219 | Advances in clinical trials for amyotrophic lateral sclerosis |
| Q37254313 | Altered lipid metabolism in brain injury and disorders |
| Q38918965 | An anthocyanin-enriched extract from strawberries delays disease onset and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q47782678 | An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe |
| Q89964362 | Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review |
| Q80142171 | Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis |
| Q37647941 | Antioxidant gene therapy against neuronal cell death |
| Q36104969 | Antioxidant treatment for amyotrophic lateral sclerosis |
| Q36075065 | Assessment of disease progression in motor neuron disease |
| Q36481118 | Biomarkers for amyotrophic lateral sclerosis |
| Q64079969 | Biomarkers in Motor Neuron Disease: A State of the Art Review |
| Q33392844 | Biomarkers in amyotrophic lateral sclerosis |
| Q37523903 | Biomarkers in amyotrophic lateral sclerosis: facts and future horizons |
| Q33767845 | Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? |
| Q45234238 | Blood volatile organic compounds as potential biomarkers for amyotrophic lateral sclerosis: an animal study in the SOD1 G93A mouse |
| Q46931123 | Brain oxidative stress induced by obstructive jaundice in rats |
| Q38007362 | CSF markers in amyotrophic lateral sclerosis |
| Q34369439 | Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). |
| Q28392768 | Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis |
| Q48961308 | DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. |
| Q35231353 | DJ-1 knockout augments disease severity and shortens survival in a mouse model of ALS. |
| Q48141250 | Differential contribution of microglia and monocytes in neurodegenerative diseases. |
| Q38515148 | Disturbance of redox homeostasis as a contributing underlying pathomechanism of brain and liver alterations in 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. |
| Q47782687 | Edaravone and its clinical development for amyotrophic lateral sclerosis |
| Q88772703 | Emerging Links between Lipid Droplets and Motor Neuron Diseases |
| Q37909351 | Emerging drugs for amyotrophic lateral sclerosis |
| Q26800781 | Endoplasmic Reticulum Stress Interacts With Inflammation in Human Diseases |
| Q91811242 | Existing and Emerging Metabolomic Tools for ALS Research |
| Q39823079 | Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis |
| Q96960158 | FABP7 upregulation induces a neurotoxic phenotype in astrocytes |
| Q38856405 | Further development of biomarkers in amyotrophic lateral sclerosis. |
| Q37593544 | GDE2 is essential for neuronal survival in the postnatal mammalian spinal cord. |
| Q36251872 | Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS) |
| Q38989886 | Glutathione peroxidase 4: a new player in neurodegeneration? |
| Q40470158 | Gly482Ser PGC-1α Gene Polymorphism and Exercise-Related Oxidative Stress in Amyotrophic Lateral Sclerosis Patients. |
| Q35806256 | Humoral factors in ALS patients during disease progression. |
| Q51805143 | Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. |
| Q62059282 | Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients |
| Q93053142 | Inhibition of Mitochondrial ROS by MitoQ Alleviates White Matter Injury and Improves Outcomes after Intracerebral Haemorrhage in Mice |
| Q40245798 | Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis |
| Q46135234 | Introduction to supplement: the current status of treatment for ALS. |
| Q37043070 | Is SOD1 loss of function involved in amyotrophic lateral sclerosis? |
| Q41874688 | MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS |
| Q64087673 | Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions |
| Q36745271 | Mitochondria in neurodegeneration |
| Q36444334 | Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target? |
| Q91048657 | Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent |
| Q37952528 | Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis |
| Q82607328 | Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis |
| Q36437332 | Motor neuron-immune interactions: the vicious circle of ALS. |
| Q33924917 | NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study |
| Q36562655 | Naturally occurring variation in the Glutathione-S-Transferase 4 gene determines neurodegeneration after traumatic brain injury |
| Q49334640 | Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease. |
| Q37247387 | Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis |
| Q36732766 | Nrf2--a therapeutic target for the treatment of neurodegenerative diseases |
| Q55262112 | Origin and pathophysiology of protein carbonylation, nitration and chlorination in age-related brain diseases and aging. |
| Q64982512 | Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View. |
| Q35094635 | Oxidative stress biomarkers in sporadic ALS |
| Q99555756 | PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction |
| Q47965250 | Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes |
| Q30494108 | Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. |
| Q35828459 | Physiological antioxidative network of the bilirubin system in aging and age-related diseases |
| Q36615226 | Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease |
| Q39033807 | Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. |
| Q34299611 | Possible association between expression of chemokine receptor-2 (CCR2) and amyotrophic lateral sclerosis (ALS) patients of North India |
| Q42687960 | Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis |
| Q38058054 | Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. |
| Q24678722 | Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis |
| Q92063917 | Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress |
| Q30445597 | R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. |
| Q58125223 | RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis |
| Q35764195 | RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1. |
| Q34571459 | Reduced oxidative damage in ALS by high-dose enteral melatonin treatment |
| Q37051065 | Role of Lipids in Brain Injury and Diseases |
| Q41488070 | Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications |
| Q37101247 | SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration |
| Q38776278 | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial |
| Q48258033 | Sigma-1 Receptor in Motoneuron Disease |
| Q34139329 | Signaling and cytotoxic functions of 4-hydroxyalkenals. |
| Q40095201 | Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity |
| Q33919781 | Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis |
| Q57666825 | Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration |
| Q46525827 | Sublethal dose of 4-hydroxynonenal reduces intracellular calcium in surviving motor neurons in vivo |
| Q38969736 | TDP-43/FUS in motor neuron disease: Complexity and challenges. |
| Q36681472 | Telomere shortening leads to earlier age of onset in ALS mice |
| Q64104414 | The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor-Binding Proteins in the Nervous System |
| Q42413520 | The peroxisome proliferator-activated receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis |
| Q36878198 | The wobbler mouse, an ALS animal model |
| Q37198692 | Therapy development for ALS: lessons learned and path forward |
| Q33497640 | Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients |
| Q41590764 | Yeast genetic interaction screen of human genes associated with amyotrophic lateral sclerosis: identification of MAP2K5 kinase as a potential drug target |